Key Highlights

  • NewCardio filed actively with the SEC from 2008 through the start of 2012, then stopped, with its last current report on file dating to January 2012.
  • The company was a Delaware-incorporated, California-based cardiac-diagnostics venture focused on computerized ECG analysis software.
  • NWCI trades near $0.0001 with a Market Capitalisation in the low single-thousands of dollars, consistent with a defunct shell.
  • No verifiable current product, regulatory clearance, or financing explains attention around the shares in the last closing session.

NewCardio, Inc. (OTC:NWCI) is a reminder that a promising medical-technology story can fade into a dormant ticker within a few short years. Once a Silicon Valley developer of computerised electrocardiogram analysis technology, NewCardio now trades as a sub-penny shell priced at a fraction of a cent, with a Market Value in the low thousands of dollars.

Company and Latest Development

NewCardio was a Delaware-incorporated, California-based cardiac-diagnostics company that set out to improve the interpretation of ECG data through proprietary software and signal-processing methods, targeting more accurate detection of cardiac conditions.

According to SEC EDGAR, the entity filed actively from 2008 through the start of 2012, producing a dense record of registration statements, quarterly and annual reports, and current reports. That filing cadence stopped in early 2012, its last current report on file dates to January 2012, after which the company ceased to be an active, current SEC reporter.

What Is Driving Attention Around NWCI?

No confirmed catalyst underpins recent interest in NWCI. At a quoted price near $0.0001, the stock sits deep in penny-stock territory, where thin trading can produce outsized percentage moves unrelated to news.

There is no verifiable current product, regulatory clearance, or financing to explain attention around the shares.

Key Numbers and Company Position

Verifiable current figures are scarce. Market data list NWCI near $0.0001 with a market capitalisation in the low single-thousands of dollars and no analyst coverage, consistent with a defunct shell, though not independently confirmed.

Because NewCardio has not filed financial statements since around 2012, there is no current, audited picture of cash, revenue, or liabilities.

What Could Come Next?

For a long-dormant nano-cap, the realistic paths are corporate: a change of control, a Reverse merger that repurposes the shell, a name change, or a formal delisting. None is confirmed for NewCardio.

Any genuine update would surface first through SEC EDGAR or OTC Markets disclosure. In the medical-device sector more broadly, ECG and cardiac-monitoring technology remains an active field, but that industry backdrop does not translate into a verified catalyst for this specific, inactive ticker.

Risks to Watch

NWCI carries the classic deep-penny risk profile: minimal liquidity, opaque and outdated financials, wide bid-ask spreads, and a high probability of total loss. Non-reporting shells are also prone to promotional activity, so any unverified news warrants scepticism.

Without current disclosure, the Equity cannot be reliably valued, and any revival scenario would likely involve substantial dilution.

A Cardiac-Diagnostics Story Stuck in 2012

NewCardio, Inc. is best viewed today as a dormant, sub-penny shell rather than the emerging cardiac-diagnostics company it once aimed to be. Its verifiable record, a Delaware incorporation, a California base, an electromedical-device focus, and an active filing history that ended in early 2012, is firmly in the past.

For investors, the only meaningful watch-items are primary-source signals: a resumption of reporting, a new OTC Markets disclosure, or a change-of-control filing.